PAVmed Inc

NASDAQ:PAVM  
4.34
-0.12 (-2.69%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)355.72M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.03 Million
Adjusted EPS-$0.12
See more estimates
10-Day MA$4.57
50-Day MA$4.56
200-Day MA$2.74
See more pivots

PAVmed Inc Stock, NASDAQ:PAVM

One Grand Central Place, 60 East 42nd Street, New York, New York 10165
United States of America
Phone: +1.212.949.4319
Number of Employees: 25

Description

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy, and Emerging Innovations. The GI health division comprises of EsoGuard esophageal DNA laboratory developed test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus technology. The minimally invasive interventions division offers CarpX minimally invasive surgical device for carpal tunnel syndrome. The infusion therapy division includes PortIO implantable intraosseous vascular accedd device and NextFlo highly accurate disposable intravenous infusion platform technology. The emerging innovations divisions consists of non-invasive laser-based glucose monitoring, single-use ventilators, resorbable pediatric ear tubes and mechanical circulatory cannulas. The company was founded on June 26, 2014 and is headquartered in New York, NY.